"9.6 per 100 patients-years) treated with OLUMIANT 2 mg, and 500 patients (55.3 per 100 patient-years) treated with baricitinib 4 mg.</p><p>In the 0 to 52-week exposure population, the most commonly reported infections with OLUMIANT were viral upper respiratory tract infection, upper respiratory tract infection, urinary tract infection, and bronchitis.</p><p><span class=\\\"Italics\\\">Serious Infections</span> – During the 16-week treatment period, serious infections were reported in 13 patients (4.2 per 100 patient-years) treated with placebo, 5 patients (3.6 per 100 patient-years) treated with OLUMIANT 2 mg, and 11 patients (3.7 per 100 patient-years) treated with baricitinib 4 mg.</p><p>During 0 to 52-week exposure, serious infections were reported in 14 patients (4.2 per 100 patient-years) treated with OLUMIANT 2 mg and 32 patients (3.5 per 100 patient-years) treated with baricitinib 4 mg.</p><p>In the 0 to 52-week exposure population, the most commonly reported serious infections with OLUMIANT were pneumonia, herpes zoster, and urinary tract infection <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s36\\\">5.1</a>)]</span>.</p><p><span class=\\\"Italics\\\">Tuberculosis</span> – During the 16-week treatment period, no events of tuberculosis were reported.</p><p>During 0 to 52-week exposure, events of tuberculosis were reported in 0 patients treated with OLUMIANT 2 mg and 1 patient (0.1 per 100 patient-years) treated with baricitinib 4 mg <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s36\\\">5.1</a>)]</span>.</p><p>Cases of disseminated tuberculosis were also reported.</p><p><span class=\\\"Italics\\\">Opportunistic Infections (excluding tuberculosis)</span> – During the 16-week treatment period, opportunistic infections were reported in 2 patients (0.6 per 100 patient-years) treated with placebo, 0 patients treated with OLUMIANT 2 mg and 2 patients (0.7 per 100 patient-years) treated with baricitinib 4 mg. During 0 to 52-week exposure, opportunistic infections were reported in 1 patient (0.3 per 100 patient-years) treated with OLUMIANT 2 mg and 5 patients (0.6 per 100 patient-years) treated with baricitinib 4 mg <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s36\\\">5.1</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s57\\\"></a><a name=\\\"section-5.1.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Malignancies</span></p><p>During the 16-week treatment period, malignancies excluding non-melanoma skin cancers (NMSC) were reported in 0 patients treated with placebo, 1 patient (0.7 per 100 patient-years) treated with OLUMIANT 2 mg, and 1 patient (0.3 per 100 patient-years) treated with baricitinib 4 mg.</p><p>During the 0 to 52-week treatment period, malignancies excluding NMSC were reported in 2 patients (0.6 per 100 patient-years) treated with OLUMIANT 2 mg and 6 patients (0.7 per 100 patient-years) treated with baricitinib 4 mg <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s40\\\">5.3</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s58\\\"></a><a name=\\\"section-5.1.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Thrombosis</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s59\\\"></a><a name=\\\"section-5.1.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Venous Thrombosis</span> – During the 16-week treatment period, venous thromboses (deep vein thrombosis or pulmonary embolism) were reported in 0 patients treated with placebo, 0 patients treated with OLUMIANT 2 mg, and 5 patients (1.7 per 100 patient-years) treated with baricitinib 4 mg. During the 0 to 52-week treatment period, venous thromboses were reported in 2 patients (0.6 per 100 patient-years) treated with OLUMIANT 2 mg and 7 patients (0.8 per 100 patient-years) treated with baricitinib 4 mg.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s60\\\"></a><a name=\\\"section-5.1.6\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Arterial Thrombosis</span> – During the 16-week treatment period, arterial thromboses were reported in 1 patient treated with placebo (0.3 per 100 patient-years), 2 patients (1.4 per 100 patient-years) treated with OLUMIANT 2 mg, and 2 patients (0.7 per 100 patient-years) treated with baricitinib 4 mg. During the 0 to 52-week treatment period, arterial thromboses were reported in 3 patients (0.9 per 100 patient-years) treated with OLUMIANT 2 mg and 3 patients (0.3 per 100 patient-years) treated with baricitinib 4 mg.</p><p><span class=\\\"Underline\\\">Laboratory Abnormalities</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s61\\\"></a><a name=\\\"section-5.1.7\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Neutropenia</span> – During the 16-week treatment period, neutrophil counts below 1000 cells/mm<span class=\\\"Sup\\\">3</span> occurred in 0% of patients treated with placebo, 0.6% of patients treated with OLUMIANT 2 mg, and 0.3% of patients treated with baricitinib 4 mg. There were no neutrophil counts below 500 cells/mm<span class=\\\"Sup\\\">3</span> observed in any treatment group <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s36\\\">5.1</a>, <a href=\\\"#s46\\\">5.8</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s62\\\"></a><a name=\\\"section-5.1.8\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Platelet Elevations</span> – During the 16-week treatment period, increases in platelet counts above 600,000 cells/mm<span class=\\\"Sup\\\">3</span> occurred in 1.1% of patients treated with placebo, 1.1% of patients treated with OLUMIANT 2 mg, and 2.0% of patients treated with baricitinib 4 mg. Mean platelet count increased by 3000 cells/mm<span class=\\\"Sup\\\">3</span> at 16 weeks in patients treated with placebo, by 15,000 cells/mm<span class=\\\"Sup\\\">3</span> at 16 weeks in patients treated with OLUMIANT 2 mg and by 23,000 cells/mm<span class=\\\"Sup\\\">3</span> in patients treated with baricitinib 4 mg.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s63\\\"></a><a name=\\\"section-5.1.9\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Liver Enzyme Elevations</span> – Events of increases in liver enzymes ≥3 times the ULN were observed in patients treated with OLUMIANT <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s46\\\">5.8</a>)]</span>.</p><ul class=\\\"Disc\\\"><li>During the 16-week treatment period, ALT elevations ≥3 times the ULN occurred in 1.0% of patients treated with placebo, 1.7% of patients treated with OLUMIANT 2 mg, and 1.4% of patients treated with baricitinib 4 mg.</li><li>During the 16-week treatment period, AST elevations ≥ 3 times the ULN occurred in 0.8% of patients treated with placebo, 1.3% of patients treated with OLUMIANT 2 mg, and 0.8% of patients treated with baricitinib 4 mg.</li><li>In a phase 3 study of DMARD naive patients, during the 24-week treatment period, ALT and AST elevations ≥3 times the ULN occurred in 1.9% and 0% of patients treated with methotrexate monotherapy, 1.9% and 1.3% of patients treated with baricitinib 4 mg monotherapy, and 4.7% and 1.9% of patients treated with baricitinib 4 mg plus methotrexate.</li></ul></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s64\\\"></a><a name=\\\"section-5.1.10\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Lipid Elevations</span> – In controlled clinical trials, OLUMIANT treatment was associated with dose-related increases in lipid parameters including total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol. Elevations were observed at 12 weeks and remained stable thereafter. During the 12-week treatment period, changes in lipid parameters are summarized below:</p><ul class=\\\"Disc\\\"><li>Mean LDL cholesterol increased by 8 mg/dL in patients treated with OLUMIANT 2 mg and by 14 mg/dL in patients treated with baricitinib 4 mg.</li><li>Mean HDL cholesterol increased by 7 mg/dL in patients treated with OLUMIANT 2 mg and by 9 mg/dL in patients treated with baricitinib 4 mg.</li><li>The mean LDL/HDL ratio remained stable.</li><li>Mean triglycerides increased by 7 mg/dL in patients treated with OLUMIANT 2 mg and by 15 mg/dL in patients treated with baricitinib 4 mg.</li></ul><p><span class=\\\"Italics\\\">[See Warnings and Precautions (<a href=\\\"#s46\\\">5.8</a>)].</span></p><p>Creatine Phosphokinase (CPK) – OLUMIANT treatment was associated with increases in CPK within one week of starting OLUMIANT and plateauing after 8 to 12 weeks. At 16 weeks, the mean change in CPK for OLUMIANT 2 mg and baricitinib 4 mg was 37 IU/L and 52 IU/L, respectively.</p><p>Creatinine – In controlled clinical trials, dose-related increases in serum creatinine were observed with OLUMIANT treatment. At 52 weeks, the mean increase in serum creatinine was less than 0.1 mg/dL with baricitinib 4 mg. The clinical significance of the observed serum creatinine increases is unknown.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s65\\\"></a><a name=\\\"section-5.1.11\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Other Adverse Reactions</span></p><p>Other adverse reactions are summarized in <a href=\\\"#t8\\\">Table 8</a>.</p><a name=\\\"t8\\\"></a><table width=\\\"100%\\\"><caption><span>Table 8: Adverse Reactions Occurring in Greater Than or Equal to 1% of OLUMIANT 2 mg and Baricitinib 4 mg Treated Patients in Placebo-Controlled Trials for Rheumatoid Arthritis</span></caption><col align=\\\"left\\\" width=\\\"30.117%\\\"/><col align=\\\"left\\\" width=\\\"23.294%\\\"/><col align=\\\"left\\\" width=\\\"23.294%\\\"/><col align=\\\"left\\\" width=\\\"23.294%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Includes acute sinusitis, acute tonsillitis, chronic tonsillitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinobronchitis, sinusitis, tonsillitis, tracheitis, and upper respiratory tract infection.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Includes eczema herpeticum, genital herpes, herpes simplex, ophthalmic herpes simplex, and oral herpes.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"3\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Events</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Weeks 0-16</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Placebo</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">OLUMIANT</span><br/><span class=\\\"Bold\\\">2 mg</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Baricitinib</span><br/><span class=\\\"Bold\\\">4 mg</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">n=1070</span><br/><span class=\\\"Bold\\\">(%)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">n=479</span><br/><span class=\\\"Bold\\\">(%)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">n=997</span><br/><span class=\\\"Bold\\\">(%)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Upper respiratory tract infections<span class=\\\"Sup\\\">a</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">11.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">16.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">14.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Nausea</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">1.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">2.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">2.8</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Herpes simplex<span class=\\\"Sup\\\">b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">1.8</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Herpes zoster</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">1.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">1.4</td></tr></tbody></table><p>Additional adverse drug reactions occurring in fewer than 1% of patients: acne.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s66\\\"></a><a name=\\\"section-5.1.12\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Bold\\\">Adverse Reactions in Patients with COVID-19</span></p><p>The safety of OLUMIANT was evaluated in two randomized, double-blind, placebo-controlled clinical trials of hospitalized adults with COVID-19 for up to 29 days, in which 1307 patients received at least one dose of OLUMIANT 4 mg once daily, and 1310 patients received placebo, for up to 14 days or until hospital discharge, whichever occurred first.  In these studies, prophylaxis for venous thromboembolic event (VTEs) was recommended or required for all patients unless a major contraindication was noted.</p><p>Overall, the safety profile observed in patients with COVID-19 treated with OLUMIANT was consistent with the safety profile in patients with rheumatoid arthritis.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s67\\\"></a><a name=\\\"section-5.1.13\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Overall Infections</span> – During the first 29 days of the randomized clinical trials, infections were reported in 194 patients (14.8%) treated with OLUMIANT 4 mg and by 219 patients (16.7%) treated with placebo. The most commonly reported infection with OLUMIANT was pneumonia (3.1%).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s68\\\"></a><a name=\\\"section-5.1.14\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Serious Infections</span> – During the first 29 days of the randomized clinical trials, serious infections were reported in 98 patients (7.5%) treated with OLUMIANT 4 mg and 120 patients (9.2%) treated with placebo. The most commonly reported serious infections with OLUMIANT were COVID-19 pneumonia (2.1%) and septic shock (2.1%).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s69\\\"></a><a name=\\\"section-5.1.15\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Opportunistic Infections</span> – During the first 29 days of the randomized clinical trials, opportunistic infections were reported in 12 patients (0.9%) treated with OLUMIANT 4 mg and 14 patients (1.1%) treated with placebo. Tuberculosis was reported in 1 patient (0.1%) treated with OLUMIANT 4 mg and 0 patients treated with placebo.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s70\\\"></a><a name=\\\"section-5.1.16\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Venous Thrombosis Events</span> - During the first 29 days of the randomized clinical trials, pulmonary embolism was reported in 20 patients (1.5%) treated with OLUMIANT 4 mg and 11 patients (0.8%) treated with placebo. Deep vein thrombosis was reported in 20 patients (1.5%) treated with OLUMIANT 4 mg and 18 patients (1.4%) treated with placebo.</p><p>Adverse drug reactions in greater than or equal to 1% of patients in trials for COVID-19 are summarized in <a href=\\\"#t9\\\">Table 9</a>.</p><a name=\\\"t9\\\"></a><table width=\\\"100%\\\"><caption><span>Table 9: Adverse Reactions That Occurred in Greater Than or Equal to 1% of Patients Treated with OLUMIANT 4 mg During the First 29 Days in Placebo-Controlled Trials for COVID-19</span></caption><col align=\\\"left\\\" width=\\\"55.719%\\\"/><col align=\\\"left\\\" width=\\\"17.573%\\\"/><col align=\\\"left\\\" width=\\\"26.709%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> As assessed by measured values within the clinical trial database. Frequencies are based on shifts from pre-treatment to post-treatment (with number at risk as the denominator), except for ALT and AST for which frequencies are based on observed elevation during treatment.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Creatine phosphokinase frequencies presented in the table were available for a single trial (COVID II) in patients with COVID-19 and do not represent integrated data.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo<br/><br/>N = 1310</span><br/><span class=\\\"Bold\\\">n (%)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">OLUMIANT</span><br/><span class=\\\"Bold\\\">4 mg<br/>N = 1307</span><br/><span class=\\\"Bold\\\">n (%)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">ALT ≥3 x ULN<span class=\\\"Sup\\\">a</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">201(16.0)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">230 (18.1)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">AST ≥3 x ULN<span class=\\\"Sup\\\">a</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">117 (9.4)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">149 (11.8)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Thrombocytosis &gt;600,000 cells/mm<span class=\\\"Sup\\\">3a</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">34 (4.6)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">59 (7.9)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Creatine phosphokinase (CPK) &gt;5 x ULN<span class=\\\"Sup\\\">a, b</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">38 (4.7)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">36 (4.5)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Neutropenia &lt;1000 cells/mm<span class=\\\"Sup\\\">3a</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">22 (1.8)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">26 (2.2)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Deep vein thrombosis</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">18 (1.4)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">20 (1.5)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Pulmonary embolism</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">11 (0.8)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">20 (1.5)</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Urinary tract infection</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13 (1.0)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">19 (1.5)</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s71\\\"></a><a name=\\\"section-5.1.17\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Bold\\\">Adverse Reactions in Patients with Alopecia Areata</span></p><p>The safety of OLUMIANT was evaluated in two placebo-controlled trials in patients with severe alopecia areata. Patients were randomized to placebo (371 patients), OLUMIANT 2 mg (365 patients), or OLUMIANT 4 mg (540 patients). Of these, a total of 845 patients were treated with OLUMIANT for at least 1 year.</p><p><a href=\\\"#t10\\\">Table 10</a> summarizes adverse reactions that occurred at a frequency of at least 1% in patients treated with OLUMIANT 2 mg once daily or OLUMIANT 4 mg once daily and more frequently than in patients treated with placebo during the 36-week placebo-controlled period of the alopecia areata clinical trials.</p><a name=\\\"t10\\\"></a><table width=\\\"100%\\\"><caption><span>Table 10: Adverse Reactions That Occurred in ≥1% of Patients Treated with OLUMIANT 2 mg or OLUMIANT 4 mg in Alopecia Areata Trials</span></caption><col align=\\\"left\\\" width=\\\"35.725%\\\"/><col align=\\\"left\\\" width=\\\"21.425%\\\"/><col align=\\\"left\\\" width=\\\"21.425%\\\"/><col align=\\\"left\\\" width=\\\"21.425%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> %-study size adjusted percentages.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> URTI includes: acute sinusitis, influenza, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection, viral upper respiratory tract infection, viral sinusitis, viral pharyngitis, respiratory tract infection viral, rhinovirus infection and adenoiditis</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> Acne includes: acne and dermatitis acneiform.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> Hyperlipidemia includes: hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia, dyslipidaemia, lipids increased, low density lipoprotein increased, blood cholesterol increased, and blood triglycerides increased.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">e</span> UTI includes: cystitis, urinary tract infection, white blood cells urine positive, urinary tract infection bacterial, and pyelonephritis.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">f</span> Liver enzyme elevations includes: transaminases increased, aspartate aminotransferase increased, alanine aminotransferase increased, hepatic enzyme increased, gamma-glutamyl transferase increased, and hepatic function abnormal.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">g</span> Folliculitis was most commonly localized in the scalp region associated with hair regrowth</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">h</span> LRTI includes: bronchitis, bronchiolitis, lower respiratory tract infection, pneumonia, COVID-19 pneumonia, and respiratory tract infection.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">i</span> Genital Candida infections includes: vulvovaginal candidiasis, vulvovaginal mycotic infection, and genital infection fungal.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">j</span> Neutropenia includes: neutropenia and neutrophil count decreased.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">k</span> Abdominal pain includes: abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal discomfort.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Adverse Reaction</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Weeks 0-36</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Placebo</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">OLUMIANT</span><br/><span class=\\\"Bold\\\">2 mg</span></td><td align=\\\"center\\\" class=\\\"Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">OLUMIANT</span><br/><span class=\\\"Bold\\\">4 mg</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">N=371</span><br/><span class=\\\"Bold\\\">(%)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">N=365</span><br/><span class=\\\"Bold\\\">(%)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">N=540</span><br/><span class=\\\"Bold\\\">(%)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Upper respiratory tract infections<span class=\\\"Sup\\\">b</span><br/>(URTI)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">19.9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">18.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">21.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Headache</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">5.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">5.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">6.6</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Acne<span class=\\\"Sup\\\">c</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">2.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">5.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">5.9</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Hyperlipidemia<span class=\\\"Sup\\\">d</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">3.0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">3.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">5.9</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Blood creatine phosphokinase increased</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">1.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">4.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Urinary tract infections (UTI)<span class=\\\"Sup\\\">e</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">2.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">3.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">3.7</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Liver enzyme elevations<span class=\\\"Sup\\\">f</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">3.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Folliculitis<span class=\\\"Sup\\\">g</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.2</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Fatigue</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.1</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.2</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Lower respiratory tract infections (LRTI)<span class=\\\"Sup\\\">h</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Nausea</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.7</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.0</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Genital Candida infections<span class=\\\"Sup\\\">i</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Anemia</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">1.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Neutropenia<span class=\\\"Sup\\\">j</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">1.3</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Abdominal pain<span class=\\\"Sup\\\">k</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">2.2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">3.8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.9</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Herpes zoster</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.5</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">1.4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.9</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Weight increased</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">1.6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">0.9</td></tr></tbody></table><p>In patients treated with any dose of baricitinib, adverse reactions that occurred in fewer than 1% of patients include arterial thrombosis, B cell lymphoma, lymphopenia, and fungal skin infections.</p><p>Additional adverse reactions observed after Week 52: venous thromboembolic events (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), and malignancy including non-melanoma skin cancer.</p><p>Overall, the adverse reactions observed in patients with alopecia areata treated with OLUMIANT were consistent with the adverse reactions in patients with rheumatoid arthritis.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"90375-7\\\"><a name=\\\"s72\\\"></a><a name=\\\"section-5.2\\\"></a><p></p><h2>6.2 Postmarketing Experience</h2><p class=\\\"First\\\">The following adverse reactions have been identified during post-approval use of OLUMIANT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:</p><p><span class=\\\"Italics\\\">Immune System Disorders</span>: Drug hypersensitivity (events such as rash, urticaria, and angioedema have been reported) <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s44\\\">5.6</a>)]</span>.</p></div></section>\",\n            \"drugInteractions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34073-7\\\"><a name=\\\"s73\\\"></a><a name=\\\"section-6\\\"></a><p></p><h1>7 DRUG INTERACTIONS</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s74\\\"></a><a name=\\\"section-6.1\\\"></a><p></p><h2>7.1 Strong OAT3 Inhibitors</h2><p class=\\\"First\\\">Baricitinib exposure is increased when OLUMIANT is co-administered with strong OAT3 inhibitors (such as probenecid), hence the dosage of baricitinib should be reduced by half the recommended dose <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s14\\\">2.2</a>, <a href=\\\"#s15\\\">2.3</a>) and Clinical Pharmacology (<a href=\\\"#s103\\\">12.3</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s75\\\"></a><a name=\\\"section-6.2\\\"></a><p></p><h2>7.2 Other JAK Inhibitors or Biologic DMARDs</h2><p class=\\\"First\\\">OLUMIANT has not been studied in combination with other JAK inhibitors or with biologic DMARDs <span class=\\\"Italics\\\">[see Indications and Usage (<a href=\\\"#s9\\\">1.1</a>, <a href=\\\"#s10\\\">1.2</a>)]</span>.</p></div></section>\",\n            \"clinicalPharmacology\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34090-1\\\"><a name=\\\"s96\\\"></a><a name=\\\"section-10\\\"></a><p></p><h1>12 CLINICAL PHARMACOLOGY</h1><div class=\\\"Section\\\" data-sectioncode=\\\"43679-0\\\"><a name=\\\"s97\\\"></a><a name=\\\"section-10.1\\\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\\\"First\\\">Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Baricitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.</p><p>JAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2). In cell-free isolated enzyme assays, baricitinib had greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3. In human leukocytes, baricitinib inhibited cytokine induced STAT phosphorylation mediated by JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, or JAK2/TYK2 with comparable potencies. However, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"43681-6\\\"><a name=\\\"s98\\\"></a><a name=\\\"section-10.2\\\"></a><p></p><h2>12.2 Pharmacodynamics</h2><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s99\\\"></a><a name=\\\"section-10.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Baricitinib inhibition of IL-6 induced STAT3 phosphorylation</span> – Baricitinib administration resulted in a dose dependent inhibition of IL-6 induced STAT3 phosphorylation in whole blood from healthy subjects with maximal inhibition observed approximately 1 hour after dosing, which returned to near baseline by 24 hours. Similar levels of inhibition were observed using either IL-6 or TPO as the stimulus.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s100\\\"></a><a name=\\\"section-10.2.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Immunoglobulins</span> – Mean serum IgG, IgM, and IgA values decreased by 12 weeks after starting treatment with OLUMIANT, and remained stable through at least 52 weeks. For most patients, changes in immunoglobulins occurred within the normal reference range.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s101\\\"></a><a name=\\\"section-10.2.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">C-reactive protein</span> – In patients with rheumatoid arthritis, decreases in serum C-reactive protein (CRP) were observed as early as one week after starting treatment with OLUMIANT and were maintained throughout dosing.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s102\\\"></a><a name=\\\"section-10.2.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Cardiac Electrophysiology</span> – At a dose 10 times the maximum recommended dose, baricitinib does not prolong the QT interval to any clinically relevant extent.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"43682-4\\\"><a name=\\\"s103\\\"></a><a name=\\\"section-10.3\\\"></a><p></p><h2>12.3 Pharmacokinetics</h2><p class=\\\"First\\\">Following oral administration of OLUMIANT, peak plasma concentrations are reached approximately at 1 hour. A dose-proportional increase in systemic exposure was observed in the therapeutic dose range. The pharmacokinetics of baricitinib do not change over time. Steady-state concentrations are achieved in 2 to 3 days with minimal accumulation after once-daily administration.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s104\\\"></a><a name=\\\"section-10.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Absorption</span> – The absolute bioavailability of baricitinib is approximately 80%. An assessment of food effects in healthy subjects showed that a high-fat meal decreased the mean AUC and C<span class=\\\"Sub\\\">max</span> of baricitinib by approximately 11% and 18%, respectively, and delayed the t<span class=\\\"Sub\\\">max</span> by 0.5 hours. Administration with meals is not associated with a clinically relevant effect on exposure. In clinical studies, OLUMIANT was administered without regard to meals.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s105\\\"></a><a name=\\\"section-10.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Distribution</span> – After intravenous administration, the volume of distribution is 76 L, indicating distribution of baricitinib into tissues. Baricitinib is approximately 50% bound to plasma proteins and 45% bound to serum proteins. Baricitinib is a substrate of the Pgp, BCRP, OAT3 and MATE2-K transporters, which play roles in drug distribution.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s106\\\"></a><a name=\\\"section-10.3.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Elimination</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s107\\\"></a><a name=\\\"section-10.3.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Rheumatoid Arthritis and Alopecia Areata</span>: The total body clearance of baricitinib is 8.9 L/h in patients with rheumatoid arthritis and 11 L/h in patients with alopecia areata. Elimination half-life in patients with rheumatoid arthritis and alopecia areata is approximately 12 to 16 hours.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s108\\\"></a><a name=\\\"section-10.3.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">COVID-19:</span> The total body clearance and half-life of baricitinib is 14.2 L/h and 10.8 hours, respectively, in patients with COVID-19 who are intubated and have baricitinib administered via NG or OG tube.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s109\\\"></a><a name=\\\"section-10.3.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Metabolism</span> – Approximately 6% of the orally administered baricitinib dose is identified as metabolites (three from urine and one from feces), with CYP3A4 identified as the main metabolizing enzyme. No metabolites of baricitinib were quantifiable in plasma.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s110\\\"></a><a name=\\\"section-10.3.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Excretion</span> – Renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion as baricitinib is identified as a substrate of OAT3, Pgp, BCRP and MATE2-K from <span class=\\\"Italics\\\">in vitro</span> studies. In a clinical pharmacology study, approximately 75% of the administered dose was eliminated in the urine, while about 20% of the dose was eliminated in the feces. Baricitinib was excreted predominately as unchanged drug in urine (69%) and feces (15%).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s111\\\"></a><a name=\\\"section-10.3.6\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Specific Populations</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s112\\\"></a><a name=\\\"section-10.3.7\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Effects of Body Weight, Gender, Race, and Age</span></p><p>Body weight, gender, race, ethnicity, and age did not have a clinically relevant effect on the PK (AUC and C<span class=\\\"Sub\\\">max</span>) of baricitinib (Figure 1). The mean effects of intrinsic factors on PK parameters (AUC and C<span class=\\\"Sub\\\">max</span>) were generally within the inter-subject PK variability of baricitinib. The inter-subject variabilities (% coefficients of variation) in AUC and C<span class=\\\"Sub\\\">max</span> of baricitinib are approximately 41% and 22%, respectively, in patients with rheumatoid arthritis <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s89\\\">8.5</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s113\\\"></a><a name=\\\"section-10.3.8\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Patients with Renal Impairment</span></p><p>Baricitinib systemic exposure in AUC was increased by 1.41-, 2.22-, 4.05- and 2.41-fold for mild, moderate, severe, and ESRD (with hemodialysis) renal impairment sub-groups, respectively, compared to subjects with normal renal function. The corresponding values for increase in C<span class=\\\"Sub\\\">max</span> were 1.16-, 1.46-, 1.40- and 0.88-fold, respectively (Figure 1) <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s91\\\">8.7</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s114\\\"></a><a name=\\\"section-10.3.9\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Patients with Hepatic Impairment</span></p><p>Baricitinib systemic exposure and C<span class=\\\"Sub\\\">max</span> increased by 1.19- and 1.08-fold for the moderate hepatic impairment group, respectively, compared to subjects with normal hepatic function (<a href=\\\"#fig1\\\">Figure 1</a>) <span class=\\\"Italics\\\">[see Use in Specific Populations (<a href=\\\"#s90\\\">8.6</a>)].</span><br/><br/></p><p class=\\\"MultiMediaCaption\\\"><a name=\\\"fig1\\\"></a><span class=\\\"Bold\\\">Figure 1: Impact of Intrinsic Factors on Baricitinib Pharmacokinetics</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a, b</span></span></p><div class=\\\"Figure\\\"><a name=\\\"f02\\\"></a><img alt=\\\"Figure 1\\n\\\" src=\\\"olumiant-uspi-f1-v3.jpg\\\"/></div><p><span class=\\\"Sup\\\">a</span> Reference values for weight, age, gender, and race comparisons are 70 kg, 54 years, male, and white, respectively; reference groups for renal and hepatic impairment are subjects with normal renal and hepatic function, respectively.</p><p><span class=\\\"Sup\\\">b</span> Effects of renal and hepatic impairment on baricitinib exposure were summarized from dedicated renal and hepatic impairment studies, respectively. Effects of other intrinsic factors on baricitinib exposure were summarized from population PK analysis.</p><p><span class=\\\"Sup\\\">c</span> The recommended dose for patients with COVID-19 and severe renal impairment (eGFR 15 - &lt;30 mL/min/1.73m<span class=\\\"Sup\\\">2</span>) is 1 mg once daily. OLUMIANT is not recommended for use in patients with COVID-19 who are on dialysis, have end-stage renal disease (ESRD), or acute kidney injury (eGFR &lt;15 mL/min/1.73m<span class=\\\"Sup\\\">2</span>).  <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s19\\\">2.6</a>)]</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s115\\\"></a><a name=\\\"section-10.3.10\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Drug Interactions</span></p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s116\\\"></a><a name=\\\"section-10.3.11\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Potential for Baricitinib to Influence the PK of Other Drugs</span></p><p>In vitro, baricitinib did not significantly inhibit or induce the activity of cytochrome P450 enzymes (CYPs 3A, 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6). In clinical pharmacology studies, there were no clinically meaningful changes in the pharmacokinetics (PK) of simvastatin, ethinyl estradiol, or levonorgestrel (CYP3A substrates) when co-administered with baricitinib.</p><p><span class=\\\"Italics\\\">In vitro</span> studies suggest that baricitinib is not an inhibitor of the transporters, P-glycoprotein (Pgp) or Organic Anion Transporting Polypeptide (OATP) 1B1. In vitro data indicate baricitinib does inhibit organic anionic transporter (OAT) 1, OAT2, OAT3, organic cationic transporter (OCT) 1, OCT2, OATP1B3, Breast Cancer Resistance Protein (BCRP) and Multidrug and Toxic Extrusion Protein (MATE) 1 and MATE2-K, but clinically meaningful changes in the pharmacokinetics of drugs that are substrates for these transporters are unlikely. In clinical pharmacology studies there were no clinically meaningful effects on the PK of digoxin (Pgp substrate) or methotrexate (substrate of several transporters) when co-administered with baricitinib.</p><p>Exposure changes of drugs following co-administration with baricitinib are shown in <a href=\\\"#fig2\\\">Figure 2</a>.<br/><br/></p><p class=\\\"MultiMediaCaption\\\"><a name=\\\"fig2\\\"></a><span class=\\\"Bold\\\">Figure 2: Impact of Baricitinib on the Pharmacokinetics of Other Drugs</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span></p><div class=\\\"Figure\\\"><a name=\\\"f03\\\"></a><img alt=\\\"Figure 2\\n\\\" src=\\\"olumiant-uspi-f2-v1.jpg\\\"/></div><p><span class=\\\"Sup\\\">a</span> Reference group is administration of concomitant drug alone.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s117\\\"></a><a name=\\\"section-10.3.12\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Potential for Other Drugs to Influence the PK of Baricitinib</span></p><p><span class=\\\"Italics\\\">In vitro</span> studies suggest that baricitinib is a CYP3A4 substrate. In clinical pharmacology studies there was no effect on the PK of baricitinib when co-administered with ketoconazole (CYP3A inhibitor). There were no clinically meaningful changes in the PK of baricitinib when co-administered with fluconazole (CYP3A/CYP2C19/CYP2C9 inhibitor) or rifampicin (CYP3A inducer).</p><p><span class=\\\"Italics\\\">In vitro</span> studies suggest that baricitinib is a substrate for OAT3, Pgp, BCRP and MATE2-K. In a clinical study, probenecid administration (strong OAT3 inhibitor) resulted in an approximately 2-fold increase in baricitinib AUC<span class=\\\"Sub\\\">0-∞</span> with no effect on C<span class=\\\"Sub\\\">max</span> and t<span class=\\\"Sub\\\">max</span><span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s14\\\">2.2</a>, <a href=\\\"#s15\\\">2.3</a>) and Drug Interactions (<a href=\\\"#s74\\\">7.1</a>)]</span>. However, simulations with diclofenac and ibuprofen (OAT3 inhibitors with less inhibition potential) predicted minimal effect on the PK of baricitinib. In clinical pharmacology studies there was no clinically meaningful effect on the PK of baricitinib when co-administered with cyclosporine (Pgp and BCRP inhibitor). Co-administration with methotrexate (substrate of several transporters) did not have a clinically meaningful effect on the PK of baricitinib.</p><p>Exposure changes of baricitinib following co-administration with CYP inhibitors or inducers, transporter inhibitors, as well as methotrexate and the proton pump inhibitor, omeprazole, are shown in <a href=\\\"#fig3\\\">Figure 3</a>.<br/><br/></p><p class=\\\"MultiMediaCaption\\\"><a name=\\\"fig3\\\"></a><span class=\\\"Bold\\\">Figure 3: Impact of Other Drugs on the Pharmacokinetics of Baricitinib</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span></p><div class=\\\"Figure\\\"><a name=\\\"f04\\\"></a><img alt=\\\"Figure 3\\n\\\" src=\\\"olumiant-uspi-f3-v3.jpg\\\"/></div><p><span class=\\\"Sup\\\">a</span> Values are based on simulated studies.</p><p><span class=\\\"Sup\\\">b</span> Reference group is administration of baricitinib alone.</p></div></div></section>\",\n            \"clinicalStudies\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34092-7\\\"><a name=\\\"s120\\\"></a><a name=\\\"section-12\\\"></a><p></p><h1>14 CLINICAL STUDIES</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s121\\\"></a><a name=\\\"section-12.1\\\"></a><p></p><h2>14.1 Rheumatoid Arthritis</h2><p class=\\\"First\\\">The OLUMIANT clinical development program included two dose-ranging trials and four confirmatory phase 3 trials in patients with rheumatoid arthritis (RA). Although other doses have been studied, the recommended dosage of OLUMIANT is 2 mg once daily.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s122\\\"></a><a name=\\\"section-12.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Bold\\\">Dose-Ranging Studies</span></p><p>The dose-ranging studies RA-1 (NCT01185353) and RA-2 (NCT01469013) included a 12-week randomized comparison of baricitinib 1, 2, 4, and 8 mg orally once daily versus placebo in 301 and 145 patients, respectively.</p><p>The results from the dose-ranging studies are shown in <a href=\\\"#t11\\\">Table 11</a>. In dose-ranging Study RA-1, the observed ACR response was similar for baricitinib 1 and 2 mg daily and for baricitinib 4 and 8 mg daily, with the highest response for baricitinib 8 mg daily. In dose-ranging Study RA-2, there was not a clear trend of dose response, with similar response rates for 1 mg and 4 mg and 2 mg and 8 mg.</p><a name=\\\"t11\\\"></a><table width=\\\"100%\\\"><caption><span>Table 11: Proportion of Patients with ACR20 Response at Week 12 in Dose-Ranging RA Studies</span></caption><col align=\\\"left\\\" width=\\\"19.640%\\\"/><col align=\\\"left\\\" width=\\\"16.072%\\\"/><col align=\\\"left\\\" width=\\\"16.072%\\\"/><col align=\\\"left\\\" width=\\\"16.072%\\\"/><col align=\\\"left\\\" width=\\\"16.072%\\\"/><col align=\\\"left\\\" width=\\\"16.072%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">% ACR20 Responders</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Dose-Ranging Study</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Baricitinib</span><br/><span class=\\\"Bold\\\">1 mg daily</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Baricitinib</span><br/><span class=\\\"Bold\\\">2 mg daily</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Baricitinib</span><br/><span class=\\\"Bold\\\">4 mg daily</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Baricitinib</span><br/><span class=\\\"Bold\\\">8 mg daily</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">RA-1 (N=301)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">41</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">57</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">54</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">75</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">78</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">RA-2 (N=145)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">31</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">67</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">83</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">67</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">88</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s123\\\"></a><a name=\\\"section-12.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Bold\\\">Confirmatory Studies</span></p><p>The efficacy and safety of OLUMIANT 2 mg once daily was assessed in two confirmatory phase 3 trials. These trials were randomized, double-blind, multicenter studies in patients with active rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR)/European League Against Rheumatism 2010 criteria. Patients over 18 years of age were eligible if at least 6 tender and 6 swollen joints were present at baseline. The two studies (Studies RA-3 and RA-4) evaluated OLUMIANT 2 mg and baricitinib 4 mg.</p><p>Study RA-3 (NCT01721057) was a 24-week trial in 684 patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to conventional DMARDs (cDMARDs). Patients received OLUMIANT 2 mg or 4 mg once daily or placebo added to existing background cDMARD treatment. From Week 16, non-responding patients could be rescued to receive baricitinib 4 mg once daily. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week 12.</p><p>Study RA-4 (NCT01721044) was a 24-week trial in 527 patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to 1 or more TNF inhibitor therapies with or without other biologic DMARDs (TNFi-IR). Patients received OLUMIANT 2 mg or baricitinib 4 mg once daily or placebo added to background cDMARD treatment. From Week 16, non-responding patients could be rescued to receive baricitinib 4 mg once daily. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week 12.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s124\\\"></a><a name=\\\"section-12.1.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Clinical Response</span></p><p>The percentages of OLUMIANT-treated patients achieving ACR20, ACR50, and ACR70 responses, and Disease Activity Score (DAS28-CRP) &lt;2.6 in Studies RA-3 and RA-4 are shown in <a href=\\\"#t8\\\">Table 8</a>.</p><p>Patients treated with OLUMIANT had higher rates of ACR response and DAS28-CRP &lt;2.6 versus placebo-treated patients at Week 12 (Studies RA-3 and RA-4) (<a href=\\\"#t12\\\">Table 12</a>).</p><p>In Study RA-4, higher ACR20 response rates (<a href=\\\"#fig4\\\">Figure 4</a>) were observed as early as 1 week with OLUMIANT 2 mg versus placebo.</p><p>In Study RA-4, the proportions of patients achieving DAS28-CRP &lt;2.6 who had at least 3 active joints at the end of Week 24 were 18.2% and 10.5%, in the placebo and OLUMIANT 2 mg arms, respectively.</p><a name=\\\"t12\\\"></a><table width=\\\"100%\\\"><caption><span>Table 12: Clinical Response in RA Studies RA-3 and RA-4<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"13.457%\\\"/><col align=\\\"left\\\" width=\\\"21.636%\\\"/><col align=\\\"left\\\" width=\\\"21.636%\\\"/><col align=\\\"left\\\" width=\\\"21.636%\\\"/><col align=\\\"left\\\" width=\\\"21.636%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Patients who were rescued or discontinued treatment were considered as non-responders in the analyses.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> 95% confidence interval for the difference (∆) in response rate between OLUMIANT treatment and placebo (Study RA-3, Study RA-4).</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"4\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Percent of Patients</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">cDMARD-IR</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">TNFi-IR</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Study RA-3</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Study RA-4</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Placebo + cDMARDs<br/><br/></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">OLUMIANT<br/>2 mg/day + cDMARDs<br/><br/>∆ (95% CI)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Placebo + cDMARDs<br/><br/></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">OLUMIANT<br/>2 mg/day + cDMARDs<br/><br/>∆ (95% CI)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">N</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">228</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">229</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">176</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">174</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">ACR 20</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 12<br/>%</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">39</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">66<br/>27 (18, 35)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">27</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">49<br/>22 (12, 32)</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 24<br/>%</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">42</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">61<br/>19 (10, 28)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">27</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">45<br/>18 (8, 27)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">ACR 50</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 12<br/>%</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">34<br/>21 (13, 28)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">20<br/>12 (5, 19)</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 24<br/>%</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">21</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">41<br/>20 (12, 28)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">23<br/>10 (2, 18)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">ACR 70</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 12<br/>%</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">18<br/>15 (9, 20)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13<br/>11 (5, 16)</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 24<br/>%</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">25<br/>17 (11, 24)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">3</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13<br/>10 (4, 16)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">DAS28-CRP&lt;2.6</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 12<br/>%</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">9</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">26<br/>(10, 24)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">11<br/>(2, 12)</td></tr><tr class=\\\"Last\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Week 24<br/>%</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">11</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">31<br/>(13, 27)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">11<br/>(-1, 11)</td></tr></tbody></table><p>The effects of OLUMIANT treatment on the components of the ACR response criteria for Studies RA-3 and RA-4 are shown in <a href=\\\"#t13\\\">Table 13</a>.</p><a name=\\\"t13\\\"></a><table width=\\\"100%\\\"><caption><span>Table 13: Components of ACR Response at Week 12 in RA Studies RA-3 and RA-4<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"15.400%\\\"/><col align=\\\"left\\\" width=\\\"21.160%\\\"/><col align=\\\"left\\\" width=\\\"21.160%\\\"/><col align=\\\"left\\\" width=\\\"21.160%\\\"/><col align=\\\"left\\\" width=\\\"21.120%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Data shown are mean (standard deviation).</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> Visual analog scale: 0=best, 100=worst.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"5\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> Health Assessment Questionnaire–Disability Index: 0=best, 3=worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"3\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">cDMARD-IR</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">TNFi-IR</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Study RA-3</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" colspan=\\\"2\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Study RA-4</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Placebo<br/>+ cDMARDs</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">OLUMIANT<br/>2 mg/day<br/>+ cDMARDs</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">Placebo<br/>+ cDMARDs</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">OLUMIANT<br/>2 mg/day<br/>+ cDMARDs</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">N</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">228</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">229</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">176</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"bottom\\\"><span class=\\\"Bold\\\">174</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Number of Tender Joints (0-68)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">24 (15)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">24 (14)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">28 (16)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">31 (16)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Week 12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">15 (14)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">11 (13)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">20 (16)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">19 (18)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Number of Swollen Joints (0-66)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13 (7)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">14 (9)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">17 (11)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">19 (12)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\">     Week 12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">8 (8)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5 (6)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">12 (10)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">10 (12)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Pain</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">57 (23)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">60 (21)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">65 (19)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">62 (22)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Week 12</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">43 (24)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">34 (25)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">55 (25)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">46 (28)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" colspan=\\\"5\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Patient Global Assessment</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Baseline</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">60 (21)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">62 (20)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">66 (19)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">67 (19)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">     Week 12</td><td align=\\\"cen"